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B, and stand-alone Part D plan coverage in the 12-months pre- and post-index 
date and have > 1 claim for psoriasis (ICD-9CM code 696.1) in the 12-month pre-
index period. Exclusion criteria included presence of other conditions for which 
these biologics are indicated, or receipt of any biologic in the 12-months pre-
index. Adherence to index biologic was defined as patients with proportion of 
days covered (PDC) > 0.80 during the 12-months post-index. Logistic regression 
analyses were conducted to determine the factors associated with being adher-
ent. RESULTS: Our sample included 2,707 patients newly initiating biologics. 
Overall, mean PDC for any index biologic was 0.61 and only 38% were adherent to 
their index biologic in the 12 months following initiation. Mean PDC and adherence 
rates were similar between physician-administered and self-administered agents, 
but there were several differences by index biologic. Mean PDCs were 0.66 for 
infliximab (N= 318), 0.70 for ustekinumab (N= 280), 0.63 for adalimumab (N= 1084), 
and 0.56 for etanercept (N= 1025). Adherence rates were 49%, 43%, 41%, and 29%, 
respectively. Logistic regression indicated that older age, and female gender 
were associated with poor adherence. Index biologic was also a significant factor 
associated with being adherent. CONCLUSIONS: Adherence with biologic treat-
ment for psoriasis is poor in the Medicare population with rates < 50% across all 
biologics.
Urinary/Kidney disorders – Clinical outcomes studies
PUK2
ComParative effiCaCy of interventions for overaCtive Bladder 
syndrome: a systematiC review and networK meta-analysis
Owen R.K., Tincello D.G., Bujkiewicz S., Abrams K.
University of Leicester, Leicester, UK
ObjECTIvES: There is a plethora of interventions for the treatment of overactive 
bladder syndrome, including a course of supervised pelvic floor muscle training, 
behavioral therapy, anticholinergic medication, sacral nerve stimulation, and more 
recently, botulinum toxin type A (BoNT-A) and beta-3-adrenergic agonists. Though 
there is a large and diverse range of treatment options, there is little information 
of which of them is the most clinically effective. This is largely because trials often 
compare interventions with a placebo or with interventions of the same class; and 
so there are a limited number of trials that compare interventions of different 
classes, and thus different approaches on a head-to-head basis. METhOdS: We 
searched Medline, EMBASE, Cochrane Incontinence Group Specialized Register, 
and all relevant references for randomized controlled trials evaluating interven-
tions for OAB through to October 2014. Using Bayesian Markov Chain Monte Carlo 
(MCMC) methods, we applied a hierarchical network meta-analysis that accounts 
for the exchangeability of treatment effects between different modes of admin-
istration (e.g. extended and immediate release), between treatments within the 
same class (e.g. anticholinergics) and the residual between-study heterogeneity. 
We further adjusted for differences in baseline severity of the patient population, 
as different interventions are used at varying times in the treatment pathway. 
The primary outcomes of interest were mean change from baseline for voiding, 
urgency, and incontinence episodes. RESULTS: Preliminary results show that for 
voiding and urgency episodes, BoNT-A 200u was the most effective intervention. 
BoNT-A 300u was the most effective intervention for reducing incontinence epi-
sodes. CONCLUSIONS: BoNT-A was found to be the most effective intervention for 
reducing symptoms of OAB. Accounting for the exchangeability between different 
modes of administration and treatments within in the same class sufficiently 
increases the precision in the treatment effect estimates but maintains the inter-
pretability of the individual and diverse range of treatment options.
Urinary/Kidney disorders – Cost stUdies
PUK4
the BUdget imPaCt of treatment Pathway redesign in men with 
lower Urinary traCt symPtoms (lUts) assoCiated with Benign 
ProstatiC hyPerPlasia (BPh)
Patel S.1, Garnham A.2, Nazir J.2
1Astellas UK, Chertsey, UK, 2Astellas Pharma EMEA, Chertsey, UK
ObjECTIvES: LUTS associated with BPH (LUTS/BPH) in men may present as a 
combination of voiding, storage and post-micturition symptoms. UK prescribers 
have proposed two areas of improvement to current care: first, acknowledging 
that α -blocker monotherapy may not address bothersome storage symptoms; and 
second, building confidence in primary care to prescribe drug combinations for 
mixed symptoms. We built a model to evaluate the potential budget savings from 
implementing these treatment pathway changes. METhOdS: A model was built 
in Microsoft® Excel to depict a simplified LUTS care pathway, aligned with current 
clinical practice and NICE treatment recommendations in a hypothetical cohort 
of 10,000 men with LUTS/BPH who have moderate-to-severe storage and voiding 
symptoms. The budget impact of a proposed pathway redesign was calculated, 
which could adjust the number of men diagnosed and managed in primary care. 
Men could receive a range of treatment options, and if symptoms persisted, could 
ultimately be recommended for surgery. RESULTS: The model estimated several 
annual cost savings: –£2,964,169 by increasing the proportion of men diagnosed 
in primary rather than secondary care from 30% to 40%; –£1,623,701 by increasing 
the proportion of men receiving initial LUTS treatment in primary rather than 
secondary care from 50% to 60%; and –£4,114,738 by increasing the proportion of 
men receiving combination rather than monotherapy from 6% to 20%. A combi-
nation of all proposed changes resulted in a saving of –£8,208,061. Varying drug 
choice or cost were shown to have minimal financial impact. CONCLUSIONS: The 
pathway redesign indicates substantial savings. Specifically, increasing primary 
care diagnosis and treatment of LUTS/BPH symptoms would avoid referral costs 
and potentially delay surgery, while increasing general practitioner confidence 
per-prescription of branded (Cipro) ciprofloxacin was $149.34. The sharp decrease 
in the utilization of Trovan can be explained by the withdrawal from the market 
in 2001 because of risk of liver failure. CONCLUSIONS: Increased expenditures 
for fluoroquinolones paralleled with increased utilization. Generic drug utiliza-
tion increased dramatically after brand-name patent expiration. Fluoroquinolone 
drug utilization might be also associated with its safety profile and related disease 
treatment guidelines.
Pss41
assoCiation of oBesity with 30-day readmission rates among 
Patients hosPitalized with aCUte BaCterial sKin and sKin-strUCtUre 
infeCtions (aBsssi)
Ayyagari R.1, Revol C.2, Tang W.2, Faust E.1, Tuttle E.G.3
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Analysis 
Group, Inc, Menlo Park, CA, USA
ObjECTIvES: Obesity is associated with increased risk of soft tissue infection and 
clinical failure; however, the association between obesity and longer-term clinical 
outcomes in ABSSSI patients is not well-studied. This study compared hospital read-
mission rates between obese and non-obese ABSSSI patients. METhOdS: Adults 
(> 18 years) hospitalized with ≥ 1 primary ABSSSI diagnosis were selected from the 
Cerner HealthFacts electronic medical records database (2009-2013). The first pri-
mary ABSSSI inpatient admission was defined as the index admission. Patients 
were categorized into obese (BMI> 30) and non-obese cohorts at the index admis-
sion. Proportions of patients with all-cause and ABSSSI-related readmission to the 
same hospital within 30 days were compared between the cohorts descriptively 
(in subgroups defined by gender, age, and causative pathogen) and using multi-
variable logistic regression adjusting for hospital size, demographics, insurance 
type, causative pathogen, and important comorbidities. RESULTS: 5,823 obese and 
5,882 non-obese patients were identified. Fewer obese patients were male (47.8% vs 
55.8%), ≥ 65 years old (28.2% vs 34.3%), and admitted to teaching hospitals (70.7% vs 
73.4%). Same-hospital 30-day readmission rates were higher for obese patients for 
both all-cause (12.9% vs 11.8%, p= 0.085) and ABSSSI-related (5.3% vs 4.0% p= 0.0019) 
readmissions. ABSSSI-related readmission rates remained significantly higher for 
obese patients among males (5.1% vs 3.8%, p= 0.0086), younger patients (age < 65 
years, 5.0% vs 3.6%, p= 0.0026), and those not infected with methicillin-resistant 
staphylococcus aureus (5.3% vs 4.2%, p= 0.0049). In multivariable regressions, obese 
patients had higher odds of 30-day readmission for all-cause readmissions (obese 
vs non-obese: OR= 1.10, p= 0.0944) and significantly higher odds of ABSSSI-related 
readmissions (OR= 1.28, p= 0.0073). CONCLUSIONS: Obese ABSSSI patients experi-
enced higher rates of same-hospital ABSSSI-related readmission compared with 
non-obese patients. The association persisted in male, age < 65, and non-MRSA sub-
groups and remained significant after adjustment for confounding. Further studies 
are warranted to estimate total readmission rates, which may be underestimated 
by same-hospital readmission rates.
Pss42
BiBliometriC analysis of the worlwide sCientifiC ProdUCtion of 
oral health
Simbaqueba E., Zarama P., Robles A., Upegui A.
Unicoc University, Bogota, Colombia
ObjECTIvES: Identify and analyze the level of scientific production in the oral 
health field worldwide, by applying quantitative assessment counting meth-
ods and bibliometric analysis. METhOdS: The review was realized using the 
Scopus database, given its greater coverage according to The Academic Database 
Assessment Tool. The results were analyzed through production, dissemination, 
collaboration and bibliometric indicators, which considered the trends in publica-
tion, authors, document type, workspace, magazines, country, number of citations, 
impact factor, h-index and dissemination network. A descriptive analysis was 
performed from the public policy context in oral health, in addition to the estima-
tion of trends and state of the art investigation. RESULTS: 1.727 scientific articles 
were found through searching terms associated with “oral health” AND “public 
health” AND “public policy”. The annual growth function provided an increased 
trend since 2000. The United States, Brazil and the United Kingdom were the 
countries with the highest impact and development in the oral health field, pro-
viding 40.7% of the total references found. The production is allied especially to 
universities and research groups, mainly the University of Sao Paulo, University of 
Adelaide and University of North Carolina at Chapel Hill. The areas of knowledge 
with the greater incidence were: medicine (44.1%), Dentistry (39%) and social sci-
ences (4.8%). The search for oral health had an index h: 46. CONCLUSIONS: The 
scientific production in oral health topics shows increasing development and 
institutional affluence. It is expected that the oral health problems analyzed would 
have solutions and support from the government of the region and the allocation 
of resources for health.
Pss43
BiologiC adherenCe among Psoriasis Patients in the Us mediCare 
PoPUlation
Doshi J.A.1, Takeshita J.1, Pinto L.2, Li P.1, Yu X.1, Rao P.M.3, Vishwanathan H.2, Gelfand J.M.4
1University of Pennsylvania, Philadelphia, PA, USA, 2Amgen, Thousand Oaks, CA, USA, 
3University of Pennsylvania - The Wharton School, Philadelphia, PA, USA, 4Hospital of the 
University of Pennsylvania, Philadelphia, PA, USA
ObjECTIvES: Biologics have provided major advances in the treatment of 
plaque psoriasis. Little is known regarding adherence to biologics and factors 
associated with adherence in the Medicare population. This study is the first 
to examine adherence among Medicare patients with psoriasis newly initiating 
biologics. METhOdS: The 2009 to 2012 Medicare 100% files were used to iden-
tify patients who received infliximab, ustekinumab, adalimumab, or etanercept 
between 1/1/2010 and 12/31/2011. The date of first biologic prescription defined 
the index date. Patients were required to have fee-for-service Medicare Parts A, 
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patients was CNY159722, in patients with peritoneal dialysis for CNY96739; In 
CKD patients, the presence of acute onset of CVD events, no acute CVD events and 
patients without CVD showed that the medical costs for three groups of median 
were CNY38211.9 (11 685.1~73 358.7), ll061.4 (3 809.0 ~ 23 241.0) and 13678.7 (456.5 
~36 995.3).The indirect economic burden included loss of time and property in 
patients because of illness. In hemodialysis patients, per capita annual indirect 
costs were CNY27531.2. In peritoneal dialysis patients, per capita annual indirect 
costs were CNY96739.6. CONCLUSIONS: Economic Burden of chronic kidney dis-
ease patients with hyperphosphatemia is “catastrophic expenses” for the vast 
majority of the patient’s families. In order to protect the interests of patients, 
health insurance in China needs to constantly change the protection’s structures, 
improve the ability of insurance and expand the range of coverage.
PUK8
Use of a frenCh Claims dataBase to estimate real-world treatment 
Costs of Benign ProstatiC hyPerPlasia
Jouaville S.L.1, DiNicola S.2, Boutmy E.1
1Cededim Strategic Data, Boulogne-Billancourt, France, 2Inferential, Paris, France
ObjECTIvES: In France, health insurance coverage is mandatory for all individuals. 
Administrative information necessary for the reimbursement of healthcare costs by 
French National Health Insurance is recorded in the Vitale Card that patients use in 
every step of their care. Since 2013 this information is available in claims database 
including for each patient the comprehensive history of his/her health care expen-
ditures. This database can be accessed alone or through a linkage to an electronic 
medical record database. The objective of this study was to evaluate the usefulness 
of this newly accessible information in assessing treatment cost of Benign Prostatic 
Hyperplasia (BPH) METhOdS: Patients with a first prescription of BPH treatment and 
enrolled 1 year pre-/post index, were identified in a primary care electronic medical 
record database (CSD longitudinal patients database). Patients’ characteristics and 
medical history were analyzed. Healthcare costs, exclusively related to BPH, were 
retrieved from the Health Economic Analysis Database and evaluated according to 
healthcare services: 1) Drugs delivered, both for BPH and for urinary tract infection, 
2) Visits to physicians, 3) Laboratory and radiological exams, 4) medical and surgical 
procedures, 5) Hospitalizations. All health expenses were assessed from the payer’s 
perspective RESULTS: A total of 16 893 patients were identified of whom 4 315 (24.5%) 
were treated with phytotherapeutic and 12758 (75.5%) with allopathic treatments. 
Median age was 66 years, they had been diagnosed for less than 1 year (0.87 year), 45.9% 
had hypertension, 31.6% had dyslipidemia and 16.3% had type 2 diabetes. Total cost 
HBP treatment was averagely about Euros 450 per patients/ per year. CONCLUSIONS: 
Estimating costs related to therapies is an increasingly mandatory exercise for phar-
maceutical companies. The combination of EMR and claims allows a relevant and 
accurate analysis of health care costs from the payer’ point of view.
PUK9
“Cost of illness” analysis of ChroniC Kidney disease in the entire 
PoPUlation of the rUssian federation
Kulikov A., Serpik V.G., Abdrashitova G
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
ObjECTIvES: To conduct the “cost of illness” analysis of chronic kidney disease (CKD) 
based on the entire population of the Russian Federation. METhOdS: Information 
retrieval was in the public domain. Pharmacoeconomic analysis method “cost of 
illness” was used. Direct and indirect cost analysis was also performed. RESULTS: 
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation 
the only available epidemiological information is on the later stages of CKD (accom-
panied by the appointment of renal replacement therapy). Based on that during “cost 
of illness” analysis at the population level we have extrapolated data on the distri-
bution of patients by stage of CKD available in the article Lori A. et al. 2011. Then 
the cost of various stages of CKD (including direct and indirect costs) per patient 
was calculated. At the final stage the economic burden of CKD on the entire patient 
population in the Russian Federation was determined. The total cost for all patients 
with CKD who are in stages with I to V in the year were: CKD I – 1157758914 $, CKD 
II – 1348201542 $, CKD III – 2622796532 $, CKD IV – 218480559 $, CKD V (not receiving 
renal replacement therapy) – 890038600 $, CKD V (on hemodialysis) - 462938674 $, 
CKD V (on peritoneal dialysis) - 50407252 $, CKD V (exposed of the kidney transplant) 
- 79916759 $. Thus, the total economic burden of all stages of CKD in country scale 
was 6830521313 $ per year (1 $ = 66,0983). CONCLUSIONS: “Cost of illness” analysis 
showed the economic burden of CKD on the entire patient population of the Russian 
Federation and found that the major portion of the cost appears in the early stages 
of CKD.
PUK10
Cost of illness and the faCtors affeCting it in the Patients of 
ChroniC Kidney disease at a PUBliC tertiary Care hosPital
Ahlawat R1, Tiwari P1, D’Cruz S2
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), 
Punjab, India, 2Government Medical College & Hospital, Chandigarh, India
ObjECTIvES: Cost unaffordability is one of the major reasons for the deprived qual-
ity of life and increased mortality in chronic kidney disease (CKD) patients especially 
in patients on dialysis. However, very limited data is available on CKD cost of illness 
(COI). This study was carried out to estimate the cost of illness in the patients of 
CKD. METhOdS: This cross sectional study was carried at a renal clinic of a tertiary 
care hospital over a period of six months. COI was estimated as the sum of the direct 
and indirect cost involved. Direct cost was divided into direct medical and direct 
non-medical cost. Direct medical cost included the acquisition cost and ancillary 
cost. Direct non-medical cost included the cost of transportation & food. Indirect 
cost included the loss of productivity as a result of absence from work by patients 
and care givers. Five stages of CKD patients were divided into two groups (G1-G4, and 
G5), according to KDIGO guidelines. Costs were estimated in terms of Indian national 
rupee (INR; IUSD~INR62). RESULTS: A total of 122 patients were included in the 
in prescribing multiple drug classes may improve care for men with substan-
tial storage symptoms that have not been adequately addressed by α -blocker 
monotherapy.
PUK5
evalUating the eConomiC imPliCations of nonadherenCe and 
antiBody-mediated rejeCtion in renal transPlant reCiPients: the 
role of onCe-daily, Prolonged-release taCrolimUs in the UK setting
Muduma G.1, Odeyemi I.A.1, Pollock R.F.2
1Astellas Pharma EMEA, Chertsey, UK, 2Ossian Health Economics and Communications GmbH, 
Basel, Switzerland
ObjECTIvES: While short-term kidney graft survival has gradually improved over 
time, improvements in long-term graft survival have been more modest. One key 
clinical factor limiting improved long-term outcomes is antibody-mediated rejec-
tion (AbMR). Recent data suggest that AbMR incidence is higher in non-adherent 
patients; a factor that can be improved by reducing pill burden. The aim of the 
present study was to model the incidence and economic consequences of graft loss 
and AbMR with once-daily, prolonged-release (PR) tacrolimus versus twice-daily, 
immediate-release (IR) tacrolimus in the UK setting. METhOdS: A combined deci-
sion tree and Markov model was developed to estimate incidence of graft failure, 
AbMR and mortality in renal transplant recipients taking PR versus IR tacroli-
mus. Underlying rates of graft failure and mortality were derived from UK-specific 
sources. Proportions of patients adherent to once- and twice-daily tacrolimus were 
taken from a recent randomized trial. Relative risks of graft failure and AbMR were 
taken from a separate prospective analysis of 315 patients. Cost data were taken 
from the British National Formulary and NHS reference costs and reported in 2014 
pounds sterling. RESULTS: Switching patients from IR to PR tacrolimus would 
result in projected cost savings of GBP 4,862 per patient over five years, translat-
ing to savings of GBP 486,200 in a hypothetical 100-patient cohort. Mean absolute 
per-patient costs with PR tacrolimus were projected to be GBP 40,974 versus GBP 
45,836 with IR, with the largest saving arising from reduced dialysis costs, fol-
lowed by reduced pharmacy and AbMR treatment costs. CONCLUSIONS: Modeling 
analysis showed that using PR tacrolimus in place of IR in UK renal transplant 
recipients was associated with lower pharmacy, dialysis and AbMR treatment 
costs, with the reduction in AbMR and dialysis costs being driven by improved 
adherence to PR tacrolimus and the consequent reductions in graft loss and onset 
of AbMR.
PUK6
eConomiC BUrden of antiBody mediated rejeCtion following Kidney 
transPlantation: ComParative analysis Using the Premier hosPital 
dataBase
Irish W.1, Boscoe A.2, Ryan M.P.3, Iloeje U.4, Gunnarsson C.3, Marks W.4
1CTI Clinical Trial and Consulting Services, Raleigh, NC, USA, 2Alexion Pharmaceuticals Inc, 
Cambridge, MA, USA, 3CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 4Alexion 
Pharmaceuticals Inc, Cheshire, CT, USA
ObjECTIvES: Antibody mediated rejection (AMR) is a major cause of graft failure 
following kidney transplantation (KTx). No agents are currently approved for preven-
tion or management of AMR. Current strategies include plasmapheresis (PP) and 
intravenous immunoglobulin. Economic burden of AMR in the real-world clinical 
setting has not been studied. METhOdS: Eligible patients (age ≥ 18 years) had 
a record of a hospitalization in the Premier database between January, 2006 and 
December, 2013 and were recipients of a kidney-only transplant. We used the occur-
rence of PP up to 90 days post-transplant as an indicator of AMR. A propensity 
score-matched cohort of No AMR, having at least 2 outpatient follow up visits within 
90 days post-KTx without evidence of PP, was used for comparative analyses. Total 
number of days in the hospital and total hospital costs (US dollars) aggregated over 
the hospital visits were compared between matched cohorts using a gamma log 
link regression model. Model-based (mean) estimates are reported for AMR versus 
No AMR. RESULTS: A total of n= 215 patients with AMR (mean age was 47 ± 14 years, 
51% were male, 45% were recipients of a living donor, 19% had a previous KTx and 
15% had a history of diabetes) were matched to n= 215 No AMR patients. Mean 
total number of days in the hospital for the AMR cohort was 20 days compared to 
11 days for the No AMR cohort (p< 0.0001). Total hospital costs were 50% higher in 
the AMR cohort compared to the No AMR cohort (Mean = $135,172 versus $90,527, 
respectively; p< 0.0001), irrespective of donor type (AMR match cohort X Donor type 
(living or deceased donor) interaction: p= 0.748). CONCLUSIONS: AMR is associated 
with significant economic challenges early post-KTx and is costly to the healthcare 
system. Therapies targeted at preventing and treating AMR have important eco-
nomic and clinical implications.
PUK7
eConomiC BUrden of hyPerPhosPhatemia in ChroniC Kidney disease 
in China: a review
Li X., Yang L.
Peking University, Beijing, China
ObjECTIvES: Hyperphosphatemia in chronic kidney disease is a common com-
plication in patients with end-stage renal. This paper reviews the researches 
which were done for China’s current economic burden of hyperphosphatemia in 
chronic kidney disease. METhOdS: Using “chronic kidney disease”, “hyperphos-
phatemia in chronic kidney disease” and “economic burden” are as the key words 
to choose articles in PUBMED and Chinese journals. At the same time, the data 
of dialysis patients with CKD stages in 2012 from Beijing, Shanghai, Chengdu, 
Guangzhou and the databases of national urban basic medical insurance in 2010 
are analyzed. RESULTS: Economic burden of chronic kidney disease in patients 
with hyperphosphatemia is divided into direct and indirect costs. The direct eco-
nomic burden includes dialysis treatment and hospital costs, drug costs and car-
diovascular complications’ costs. Among them, dialysis treatment and hospital 
costs (including drug costs), per capita annual economic burden in hemodialysis 
